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         INTRODUCTION
Carcinoma of oesophagus is one of the most debilitating disease that deprives a person from the 
joy of eating food. It frustrates the patient because of the mechanical effect resulting in dysphagia and 
infiltration  to  the  nearby structures  resulting  in  excruciating  pain.  When  the  tumour  extends  into 
respiratory  tract  further  worsens  the  nutritional  status  by  aggravating  the  dysphagia  cough  and 
aspiration on swallowing and associated respiratory infection and negative nitrogen balance add to the 
problem. At the time of presentation of symptoms most of the patients are in advanced malignancy. 
Unfortunately this disease is increasing in our country due to the changing trends in people’s lifestyle 
and food habits. 
The most distressing symptom for the vast majority of patients with malignant obstruction of 
the oesophagus is dysphagia. The relief of this condition associated with nutritional and psychosocial 
support must be the primary goal of palliation. More than 70% of patients with neoplastic disease of the 
oesophagus or oesophagogastric junction at the time of diagnosis are not suitable for curative surgical 
resection (1) because of advanced local disease, extensive distant metastases, or both. Therefore, these 
patients are palliatively treated, either by surgery, radiotherapy, chemotherapy or endoscopic therapy.
At the present time, approximately 10% of patients with oesophageal cancer survive five years. 
Thus,  approximately 90% are  incurable  and will  need  some form of  palliation.  The  morbidity  of 
radiation and chemotherapy can be managed well by alterations of dosage and frequency. In selected 
patients with distal lesions, surgical therapy may offer good palliation of dysphagia at the price of 
operative risk and postresection sequelae. 
The  optimum palliative  care  for  the  majority  of  patients  with  oesophageal  cancer  should 
include the safest, most effective, and least expensive therapies that can be performed promptly as the 
need arises. All too often, quality of life is neither protected nor supported adequately between the 
stage of recognized incurability and death. 
The  overall  five-year  "cure"  rates  for  these  neoplasms  (5)  have  not  changed,  despite  the 
excellent progress made in supportive care, surgical technique, radiation, and chemotherapy except in 
highly selected patients. The reason for the persistently poor results is that oesophageal cancer is rarely 
diagnosed early enough to do curative treatment. 
General supportive care, relief of pain, restoration of adequate nutritional status, and treatment 
of specific sequelae of the carcinoma are all essential to proper therapy. No single method is adequate 
for palliating oesophageal carcinoma, especially dysphagia. 
LITERATURE REVIEW ON
PALLIATION OF CARCINOMA OESOPHAGUS 
Dysphagia literally means difficulty with eating,  but  the  term is  used clinically to  indicate 
difficulty in passage of solid and liquid boluses through the oesophagus to the stomach. The presence 
of dysphagia as a presenting symptom of oesophageal cancer usually is indicative of incurability. 
The normal oesophageal lumen measures approximately 25 mm in functional diameter. When 
the lumen diameter is decreased to 13 mm, everyone has solid food or regular diet dysphagia (2). When 
the lumen diameter is less than 18 mm, selective alteration of diet content (17) and consistency is 
necessary, depending on the characteristics of the stricture.
The  average  patient  with  carcinoma  oesophagus  has  had  significant,  easily  recognizable 
dysphagia for at least three to six months before seeking medical care. Obstructive dysphagia correlates 
with  more  than  50%  occlusion  (16)  of  the  oesophageal  lumen  and  usually  indicates  extensive 
intramural spread of the cancer. Most patients also have 5 cm (13) or more of longitudinal intramural 
oesophageal involvement at diagnosis. Sialorrhea or excessive saliva production is regularly associated 
with oesophageal obstruction that contributes to frequent spitting in daytime, as well as insomnia and 
the increased risk of aspiration pneumonia. The presence of chest pain at initial presentation is also a 
poor prognostic sign. 
Lumen  restoration  techniques  performed  with  the  aid  of  endoscopy  are  reviewed.  The 
nonsurgical  treatment  methods  discussed  are  applicable  to  those  who  have  had  prior  attempts  at 
curative and palliative therapy, as well as to those rare patients who elect to have no formal initial 
therapy for the obstructing lesion. 
The commonly used palliative therapies for Ca. oesophagus (14, 15) are:-
1. Endoscopic Dilatation - Wire guided poly vinyl bougies & wire guided and non wire guided balloon 
dilators
2. Laser Ablation
3. Thermal Ablation- BICAP Tumour probe, Argon plasma coagulation. 
4. Chemical Ablation- Chemotherapeutic Agents & sclerosants
5. Oesophageal stent- Plastic & Self Expandable Metal Stents
6. Systemic Chemotherapy
7. External Beam Radiotherapy & Brachytherapy
8. Newer Modality- Photo Dynamic Therapy, Endoscopic Mucosal Resection. 
9. Pain therapy & Nutrition care.
ENDOSCOPIC DILATATION
The first order of therapeutic protocol should be to care for the patient's nutrition, pain, and 
psychological needs. Also, the stenotic oesophageal lumen needs to be restored to a diameter sufficient 
to allow ingestion of liquids and some solid food as well to improve clearing the significant volume of 
saliva produced every day. Peroral dilation should begin as soon as possible in patients with dysphagia. 
Though there is a fear of increased risk of perforation in dilating the post radiation stricture, when 
proper instruments and techniques are used, risk in dilating a malignant stricture before, during or after 
radiation therapy is minimal.
In many cases, patients present with obviously incurable and obstructing lesions but are not 
referred for early dilation either before chemotherapy and radiation therapy are begun or after those 
treatments have failed to provide dysphagia relief. This hesitation causes the patient needless suffering 
for many weeks. Although the improved lumen patency provided by timely dilation is limited, even 
temporary relief with improved swallowing is beneficial. 
Within three to six weeks after palliative chemoradiation therapy, the optimum lumen restoring 
response can be expected.  Dysphagia may recur due to recurrent tumor,  radiation-induced stricture 
(12), or both. In any of these instances, dysphagia palliation with dilatation promptly recommended. 
Milder degrees of stricture are easier and safer to dilate than severe strictures (11). It is illogical 
to delay therapy until the patient is able to swallow only liquids, even though adequate total caloric 
intake has been possible by using a full liquid diet plus dietary supplements. 
Peroral  dilation  can  restore  oesophageal  lumen  patency,  albeit  temporarily,  to  a  diameter 
adequate  to  permit  adequate  swallowing  in  over  90% of  patients.  Either  flexible,  tapered  dilators 
(Savary) (10) passed over a guide wire or rubber dilators (Maloney) are used in progressive sizes under 
fluoroscopic  control.  Balloon  dilators  either  TTS  (Through  The  Scope)  Balloons  or  wire  guided 
balloons are used. Balloon dilators use a radial force to dilate the stricture, where as polyvinyl dilators 
use axial shearing force to dilate the lesion, thus there is more chance of complications with the latter 
dilators (12).
Most malignant strictures can be safely dilated in several sessions to a size 48F to 51F (16 to 17 
mm) (15). Lumen diameter must be greater than 39F (13 mm) (11) if solid-food dysphagia is to be at 
least partially relieved. A maintenance program for frequency of dilation is an individual matter based 
on each stricture's response. Although adequate lumen diameter can be restored by dilation, recurrent 
lumen stenosis occurs within days to a few weeks so any relief obtained usually is of short duration. 
When a short-term response is observed, the therapist needs to start planning and educating the patient 
about the next options for more prolonged palliation. 
There is no evidence that properly performed oesophageal dilation of obstructing carcinoma 
carries an unacceptable risk. Various studies reported a 80-92% success rate (11,12,14,15) for dilation. 
Minor complications (14) are chest pain, odynophagia, fever, bacteremia, minor bleed, nontransmural 
mucosal tear, broncho spasm & asymptomatic cardiac arrhythmia (12) and major complications are 
perforation (1%-4%), oesophageal hematoma (<1%), new fistulas, major bleed, pneumothorax, pleural 
effusion and rarely procedure related death (0.01%-1%) (53).   
Advantages of the dilation include simplicity, low cost, wide availability, short procedure time 
and relative safety.  Pitfalls  of the dilation are  short  lived relief,  pain during procedure,  as  disease 
progresses symptom free interval shortens. So dilation alone is inadequate for satisfactory palliation in 
most patients.
THERMAL LUMINAL RESTORATION THERAPY
THERMAL LASER ABLATION
Transendoscopic ablation of obstructing intraluminal cancer by laser thermal coagulation offers 
another relatively safe but often temporary palliation for dysphagia. Laser ablation is most helpful for 
treating lesions that are polypoid or that occlude by intraluminal growth. Laser therapy carries a higher 
risk and is less effective for cancer of the proximal oesophagus or oesophagogastric junction, tortuous 
lesions, lesion more than 5cms, very tight and hard lesions, subepithelial metastasis in a diffuse pattern, 
excessively angulated lesions, and presence of an oesophagorespiratory fistula. 
Transendoscopic laser ablation of obstructing oesophageal cancers was first described in 1982 
using  high-power  Neodymium  Yttrium-Aluminum-Garnet  (Nd:YAG)  laser(19).  The  degree  of 
dysphagia relief is less predictable after laser therapy. Successful ablation usually provides a wider 
lumen diameter and allows intake of a more solid consistency diet temporarily. The maximum benefit 
is  observed a few days after  treatment,  but dysphagia gradually recurs and requires repeat therapy 
sessions, usually every four to six weeks for life. 
One helpful application of laser ablation is for pre-stent ablation (20) of a polypoid, eccentric 
intraluminal mass. Other special cases in which laser may help include hemostasis for necrotic chronic 
bleeding lesions  and for  ablation of tumors obstructing a stent  by overgrowth at  either  end or  by 
ingrowth through an uncoated metal expandable stent. 
Laser can be used as contact (low power setting) or non-contact (high power setting) method. 
Laser used in a power setting of 40-100 W (21) in one second pulsed or continuous mode. Combination 
of vaporization and coagulation necrosis occurs during laser application. Due to the edema sometime 
initially dysphagia worsens  (22).  Ideally,  the laser  ablation should begin at  the distal  margin of a 
circumferential  lesion after  dilatation to allow safe aiming of the laser beam. The ablation is  then 
continued as the endoscope is slowly retracted 1 cm intervals. When complete luminal occlusion is 
present,  antegrade  (23)  laser  application  is  used.  Laser  ideally  delivered  with  double  channel 
endoscopes to reduce the gaseous distension and to clear the field. Patients are routinely evaluated 48 
hrs- 1 week later and retreated until maximal luminal patency is achieved. 
Although the technical success (ability to relieve the oesophageal obstruction) is approximately 
90- 97%, the functional success (the ability to maintain adequate nutrition by peroral intake) is only 
approximately 70- 85% (21, 24). Overall complication rate is 4.1% including 2% chance of perforation, 
but these can be reduced with proper case selection. 
Luminal patency in carcinoma oesophagus does not equate with improvement in dysphagia. 
Adequate nutrition is hindered to varying degrees because of tumour infiltration, radiation- or laser-
induced neuromuscular injury or fibrosis, and by the anorexia related to cancer. Mean survival time 
following thermal laser ablation is similar to other ablation methods there is no survival difference.
CONTACT THERMAL THERAPY
Electrosurgical  tumour  probe  therapy  uses  mainly  BICAP-  tumour  probe  which  has 
circumferential plates (360 degree) around the olive cylinder. It is passed over a guide wire.  Depth of 
coagulation  necrosis  varies  with  power  settings  and  the  duration  of  application.  The  procedure 
performed under fluoroscopic and endoscopic control. With BICAP tumour ablation done with Power 
setting of 50 w - 15 seconds- per each station (18).  It is recommended to do retrograde approach. In 
which the probe is pulled back over a guide wire in 1 cm interval.  Active electrode is 1.5cm in length 
so some overlap occurs in the tissue injury. 
Short segments may be treated with antegrade fashion under endoscopic guidance. In follow-up 
endoscopy (18) 48 hrs later necrotic derbies are removed and additional therapy applied on the basis of 
results. Technical success (18) and improvement in dysphagia reported in 80-90% of patients. Mean 
duration of palliation of 7.6 weeks.
BICAP  tumour  probe  is  best  suited  for  bulky  or  infiltrating  symmetrical  circumferential 
tumours.  It  is  ill  suited  for  asymmetrical  lesions,  tortuous  segments  and  tight  stenotic  tumours. 
Advantages are its low cost and ability to treat large extent of tumours in a single sitting. In advertent 
treatment of opposing or marginal non malignant tissue may result in pain and stricture.
ARGON PLASMA COAGULATION 
Argon plasma coagulation delivers monopolar electrocoagulation by using a stream of ionized 
Argon gas ignited by a high voltage discharged at the tip of a catheter probe. Application and control 
are easier. Depth of treatment is uniform and consistent although it is superficial. Problem with the 
depth of injury is too shallow so that it  is insufficient to effect relief of dysphagia associated with 
oesophageal carcinoma (16).
CHEMICAL ABLATION
Intraluminal tumor mass can be reduced by direct transendoscopic injection of absolute alcohol 
(25) and other sclerosing agents like polidocanol, sodium morrhuate or chemotherapeutic agents (27). 
Mechanism of tumour destruction is chemical necrolysis (25). Hemostasis achieved with local edema, 
vasoconstriction and thrombosis. These methods offer inexpensive and safe alternatives to therapy by 
other ablative methods; however, clinical experience is limited, and long-term follow-up is lacking. 
Transendoscopic injection of absolute alcohol, using a standard sclerotherapy needle, has been 
reported as safe, simple, and effective. Initial results are similar to laser therapy. The injected tumor 
necroses and sloughs within several days after absolute alcohol injection. Repeat sessions are needed. 
In the small number of cases reported thus far, complications have been rare, and costs above the basic 
endoscopy charge  are  minimal.  Alcohol  injection  is  contraindicated in  patients  with  infiltrating or 
minimally  protruding  tumors  due  to  the  risk  for  perforation.  Disadvantages  of  the  procedure  are 
inability control the depth of tissue injury and the lack of immediately visible tissue effects.
PHOTODYNAMIC THERAPY
Photodynamic  therapy (PDT)  begins  with  administration  of  a  chemical  photosensitizer  that 
accumulates in higher concentrations in neoplastic tissue than in normal tissue. This chemical, porfimer 
sodium is given intravenously in a dose of 2 mg/kg of body weight (26,28,29). After approximately 48 
hours,  the  area  of  cancer  is  exposed  to  a  red  light  with  a  wavelength  of  630 nm provided  by a 
continuous-wave argon-pumped dye laser via a quartz fiber passed through a standard videoendoscope. 
This light exposure initiates a chemical reaction of the porphyrin compound within the cells that leads 
to production of oxygen radicals that destroy the cells. After another 48 hours, residual tumor can be 
similarly  treated  since  an  adequate  concentration  of  the  photosensitizer  remains.  Patients  remain 
photosensitive to sunlight for one to two months and must avoid such exposure. Transient side effects 
include odynophagia, chest pain, low-grade fever and, uncommonly, minor pleural effusion. There is a 
1% perforation rate reported in the largest series to date (30).
The overall efficacy of PDT compared to Nd:YAG laser (31) is comparable. PDT is considered 
to be technically easier, less operator dependent, and less painful than laser in patients under conscious 
sedation.  The  time to  palliation  failure  of  one  month  was comparable  for  PDT and thermal  laser 
therapy. The cost of PDT is high due to the cost of porfimer sodium plus multiple endoscopies and 
hospital observation to manage the possible short-term side effects. PDT has also been used recently to 
treat tumor ingrowth (29,31) in expandable oesophageal stents.
An emerging indication for Photo Dynamic Therapy is tumour down staging (30). After PDT 
some of the initially unresectable tumours became resectable. RCTs are going on in this direction till 
then it is very costly tool for palliation of carcinoma of oesophagus.
OESOPHAGEAL STENTS
EARLY PHASE:
Little did CHARLES STENT know that his development in 1856 of a thermoplastic material 
(33,34) for dental  impressions would set in motion the development of one of the fastest  growing 
medical device technology. Other early pioneers in that field were Leroy d'Etoilles used ivory and Sir 
Charter Symonds (35) used boxwood tubes for palliation of malignant dysphagia. 
Palliation of  dysphagia due to  oesophageal  cancer  by placement  of  peroral  stents  has  been 
performed for over 100 years but was not safe and effective until the 1950s. Stents or prostheses have 
been  made  from animal  tusks,  coiled  silver  wire,  raw  gum latex,  rubber,  polyethylene,  polyvinyl 
chloride, and silicone; more recently, either stainless steel wire and space age alloys or memory metals 
have been used to construct metal stents that are expandable. 
NITINOL:
The discovery of Nitinol (Nickel & titanium alloy) developed by US Navy revolutionized the 
palliative endoprosthesis development (55). Super elastic Nitinol used mainly since it is biocompatible, 
kink resistant, self expandable, fatigue resistant and adverse to dynamic interference. So it will have 
good expansion after deployment, maintain the shape and does not migrate despite peristaltic activity.
RADIAL EXPANSION AND RADIAL COMPRESSION FORCE:
Radial expansion force is the one that makes the stent to expand outward from its center and 
resist compression. It is developed from the geometric design (55) of the stent and the property of the 
stent  material.  The  Radial  compression  force  is  the  force  exerted  by  the  luminal  wall  to 
compress/collapse the stent. So, Radial expansion force must be higher than Radial compression force 
to keep the stent in an expanded state.
FORESHORTENING:
Defined as the ‘percentage of difference between the constrained length of stent and deployed 
length of stent’.  Smaller lumen stents have less foreshortening (56). It also depends on the stent design. 
Stents with interlocking knot design have less foreshortening than braided or movable designs.
TISSUE RESPONSE TO SELF EXPANDABLE METAL STENT:  
Human studies after Self Expandable Metal Stent deployment shown an early changes (58) (<1 
month after stenting) in the form of superficial necrosis of mucosa/ tumour due to the pressure from the 
expanding the stent that migrate into the submucous space. Coated stents do not migrate, but their bare 
funnel portions do. Late changes (58) (>1 month after stenting) stent covered by a layer of collagen/ 
fibrous  tissue  and epithelialization  occurs.  Again  it  will  not  occur  in  the  covered  stents  but  their 
uncovered funnel portion develops these changes. The advantage of this phenomenon is low rate of 
stent  migration  (36),  the  disadvantage  is  lumen  compromise,  tumour  ingrowth  and  stent  became 
unremovable after stenting.  
IDEAL STENT:
The ideal stent (37) should be simple to insert,  fix and remove: painless, long lasting, safe, 
biocompatible,  incompressible,  somewhat  flexible,  thin  walled,  have  a  large  lumen,  be  able  to 
accommodate varying oesophageal dimensions, be inexpensive and require only brief hospitalization.  
The stents available in the market belong to broad categories. One is Plastic stent another group 
is Self Expandable Stent including both Metal and plastic stent. A brief summary about the property of 
these two groups of stents and comparison between and among them is given below.
PLASTIC STENTS:
Non expandable plastic tubes are made from latex, silicone or plastic material. Proximal flange/ 
funnel portion to seat at the proximal margin of the growth.  Addition of nylon, plastic or metal coils to 
the shaft of a prosthetic device also aids in anchoring and reduces displacement. 
Names of the plastic stent (39) available: 1) Tygon Tube (Tytgat), 2) Wilson-Cook stent, 3) Atkinson 
stent 4) Medoc- Celestin Tube, 5) Eska- Buess oesophageal tube, 6) Wilson-Cook Fistula prosthesis, 7) 
Eska- Buess Fistula funnel.
SELF EXPANDABLE STENT:
Self Expandable Metal Stent are made of Stainless steel (Z- stent), Elgiloy (Wallstent), Nitinol (Choo, 
Ultraflex, Esophacoil & Do stent)
SELF EXPANDABLE STENTS:
1) Wallstent  (I-  Dog  bone  type,  II-  Flare  type  and  newer  Flamingo  type)  from  Boston 
Scientific/Microvasive, Natick, Massachusetts.
2) Z – Stent (Type- A, B, C, D, E, F, Gianturco- Rosch variant & Song Variant) from Wilson-
Cook, Winston-Salem, North Carolina.
3) Ultraflex  stent  (covered  and  uncovered)  from  Boston  Scientific/Microvasive,  Natick, 
Massachusetts.
4) Choo Stent (covered and uncovered) from M.I. Tech Co.
5) Do Stent with Anti Reflux Valve from M.I. Tech Co.
6) Esophacoil from Medtronic/Instent, Eden Prairie, Minnesota. 
7) Polyflex Stent made of polyester wire mesh- Self Expanding Plastic Stent.
COMPARISON BETWEEN METALLIC STENT & PLASTIC STENT
NO PARAMETER METALLIC STENT PLASTIC STENT
1 DYNAMIC EXPANSION YES NO
2 RADIAL FORCE YES NO
3 FLEXIBILITY YES NO
4 HIGH  INTERNAL  AND  EXTERNAL 
SIZE RATIO
YES NO
5 BIO REACTIVITY MORE LESS
6 REMOVABLE NO  WHEN 
INCORPORATED
YES
7 RISK OF MIGRATION LESS MORE
8 MOLDING TO VARIOUS FIRMNESS NO YES
9 FORESHORTENING YES  EXCEPT-  Z-
STENT
NO
10 SHAPE MEMORY YES NO
11 POSITION ADJUSTMENT NO  EXCEPT  CHOO, 
DO. SONG STENTS
YES
12 OESOPHAGEAL PERFORATION LESS MORE
13 DEFORMATION CAN OCCUR NO
14 COST MORE LESS
15 MARMEN EFFECT* NITINOL STENTS NO
* Marmen effect (55)- characteristic feature of the Nitinol Stent, it denotes change of shape in response 
to temperature. There is distortion of the alloy at low temperature (martensitic effect), and then reverting 
to  their  original  shape  when  reheated  (Austenitic  effect).  Insertion  of  the  stent  is  achieved  in  the 
martensitic effect and stent inside body expands by austenitic effect (from body temperature).  
COMPARISON AMONG SELF EXPANDABLE METAL STENTS 
NO PARAMETER SELF EXPANDABLE METAL STENTSW Z U E C D
1 Compressibility  + + + + + +
2 Flexibility + + + + + +
3 Rigidity -- -- -- -- -- --
4 Large lumen -- + + + + +
5 Thin wall + + + + + +
6 Quality of eating G G G G G G
7 Tissue infiltration + + + + N N
8 Risk of migration Y Y Y N N N
9 Removability N N Y Y Y Y
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12 f) Fistula N* N* Y Y Y Y
W- Wallstent Z- Z Stent U- Ultraflex Stent
E- Esophacoil C- Choo Stent D- Do Stent 
- = No + = Yes G = Good Y= Yes N= No
* = this problem is not present in the Covered modification of this stent
PREPROCEDURE DILATATION:
Thermal  ablation  by  Nd:YAG  laser,  multipolar  electrocoagulation  probe  or  heater  probe, 
chemical ablation, argon plasma coagulation are used for pre-stent lumen preparation. It is necessary to 
plan adequate dilation over several sessions before plastic stent placement but in the SEMS overzealous 
dilatation may increase the chance of migration (32). 
DIAMETER OF THE STENT:
The diameter of stent-related lumen restoration varies between 9 and 25 mm (36,37). Plastic 
and silicone stents have lumen sizes of 9 to 12 mm (41). Metal expandable stents are advertised to have 
potential  lumen  diameters  up  to  25  mm (43);  however,  the  maximum advertised  diameter  is  not 
predictably achieved because stricture resistance often exceeds stent radial force. Metal stents with high 
radial  expansile  force can  achieve  larger  diameters  but  at  a  higher  risk of  perforation and greater 
difficulty with rapid extraction when emergent removal is indicated. 
STENT POSITIONING:
The concept for proper stent location requires that the stent extend atleast 2.5 cm above and 
below the obstructing lesion (42). For metal stents that are uncoated at each end, the 2.5-cm overlap 
measurement  should be calculated to  allow 2.5 cm of  coated stent  above and below the lesion  if 
possible. Positioning the stent in this fashion helps to compensate for the possibility of the carcinoma to 
overgrow either end or to grow through the uncoated wire mesh at either end and obstruct the lumen. 
This degree of extension beyond the lesion usually is adequate to prevent overgrowth of the cancer. 
PROCEDURAL MORBIDITY:
Stent placement is done under conscious sedation. 
When proper technique is used, the perforation risk for peroral oesophageal stents will be less 
than 5% and the mortality near zero (41). In a recent series of plastic stents, the perforation rate was 
2.8% and stent-related mortality was 1.8% (42). In patients having metal expandable stents, there were 
no perforations. The high mortality and perforation rate for plastic stent is believed to be due to the lack 
of programmed pre-stent dilation and to the type of stent and introduction apparatus used. A recent 
report says that chemotherapy does not increase the risk of complications with metal stents. Usually, 
only one or two days of hospital observation is necessary unless the patient is suffering from other 
problems associated with advanced disease.  In 90% of patients, the stent remains in position for life 
(36) and usually permits adequate swallowing of liquids and a modified soft diet.
DIFFICULT AREAS:
As with other palliative therapies, increased risk and technical difficulty are concerns for lesions 
in the cervical oesophagus (68,69,70) and at the gastroesophageal junction(45). In cervical oesophagus 
cancer  stents  are  safe  and effective  in  approximately two thirds  of  patients. Lesions  of  the  lower 
oesophageal and gastric cardia can be effectively stented. 
Rarely, stent placement can precipitate airway obstruction in the upper oesophagus. This will 
more likely occur if airway compromise by tumor involvement already exists. All patients having a 
stent placed for an oesophageal cancer cephalad to the level of the left main bronchus should have pre-
stent bronchoscopy to exclude existing airway compromise by the carcinoma. 
POST PROCEDURE:
Once some metal  stents  are  placed,  they cannot  be  easily repositioned and are  either  very 
difficult or impossible to remove. Plastic and metal stents become dislocated in 5% to 10% of cases but 
usually can be properly repositioned (44,46). 
Food impaction is usually due to a lack of patient education or noncompliance with instructions 
for proper food selection, chewing, and swallowing. Stent diet instructions, verbal and written, should 
be given to patients and family members or caregivers prior to patients' discharge from the hospital. 
POST STENT SURVIVAL:
The timing for placement of either plastic or metal expandable stents is important for procedure 
safety, quality of life, and duration of survival. This short survival (35,53) is in some measure due to 
the habit of late referral. Unfortunately, physicians in past years have neglected to refer patients for 
stents until very late in their illness. Nearly all series report the average survival after stent placement to 
range between three and five months (5, 53).
Overall survival has not been improved by metal stents compared to plastic stents (53, 41,43). 
But the stent deployment related complications are higher in plastic stents, relief of dysphagia is also 
inferior to Self Expandable Metal Stent group and post procedure hospital  admission are higher in 
plastic  stent  group.  The  unacceptable  complication  and mortality  rates  associated  with  plastic  and 
silicone oesophageal stents (41,43) occurred after development of commercial insertion devices that 
were larger and more rigid than necessary. The other major negative factor in plastic stent safety was 
the practice of single sitting dilation & stent deployment in a weakened oesophagus carcinoma patient 
resulting in complications. 
Esophageal stents  provide palliation and survival time similar to laser and other techniques 
designed to reduce dysphagia (47). Those who treat malignant oesophageal obstruction are well aware 
that  improvement  of  dysphagia  does  not  equate  with  relief  of  anorexia,  nutritional  restoration,  or 
prolonged survival. However, stents do allow the patient to enjoy the pleasures of oral alimentation and 
less time in the physician's office or hospital during the relatively short interval before death. 
BENEFITS:
The potential benefits of the ideal oesophageal stent will be easy, rapid, and safe placement, 
restoration of a predictable and adequate lumen size, optimal palliation of dysphagia and sialorrhea, 
and provision of the best possible quality of life for the known small quantity of life remaining for the 
patient with oesophageal cancer. 
OESOPHAGEAL STENT IN OESOPHAGO-RESPIRATORY FISTULAS:
A major complication of oesophageal carcinoma is the development of an oesophagorespiratory 
fistula that,  if  untreated,  typically leads to pulmonary infection and early death.  A fistula develops 
(48,49,51) in approximately 15% of cases and usually should be attributed to the natural history of this 
disease. Fistulas are the consequence of tissue destruction by carcinoma invading normal tissue. They 
may first become manifest before any therapy or after irradiation or chemotherapy has produced the 
desired  destruction  of  the  invading  cancer.  The  fistula,  however,  should  not  be  considered  a 
complication of irradiation, dilation, or other therapy for this malignancy; it is simply a natural event to 
be expected when necrotic, neoplastic tissue necroses or is removed or displaced. 
The most reasonable palliation of the problems of malignant oesophagorespiratory fistulas is 
stent plastic, silicone, or coated metal expandable (52). Effective occlusion of a fistula within minutes 
by proper stent placement is satisfying. The elimination of cough, restoration of ability to rest and sleep 
without the constant cough, and the improvement in quality of life and psychological status of the 
patient and family provides a positive experience for all concerned. 
COMPLICATIONS:
Placement of SEMS is associated with a number of complications (47) both immediate (< 2 wk 
status post stent) and late (> 2 wk status post stent). Technical complications include failure/problems 
with stent deployment or expansion, stent misplacement (immediate complication) or migration (late 
complication),  and  perforation  (both  immediate  and  late).  Chest  pain  is  often  an  immediate 
symptomatic complication. Stent occlusion (35,38,46) leading to recurrent dysphagia that may be due 
to  tumor  ingrowth/overgrowth  or  food  impaction  is  one  of  the  most  common late  complications. 
Bleeding  can  occur  early  as  well  as  late  following  stent  placement.  Several  complications  are 
considered potentially life-threatening are (53) immediate respiratory compromise, aspiration, fistula 
formation, sepsis, and ultimately, there may be procedure-related death. 
FUTURE DEVELOPMENTS:
SEMS represent a rapidly growing therapeutic field. Currently, several new SEMS are under 
development. Stent with antireflux properties is useful in the gastroesophageal junction. The new stents 
that devised to have thermal-shaped memory (85) and can rapidly change physical form under different 
temperature  conditions,  thus  allowing  for  enhanced  removability.  Indications  for  SEMS  use  are 
expanding like bronchoesophageal fistula and benign oesophageal strictures. Self  expanding plastic 
stents  and biodegradable  stents  entered the market  that  extends the indication to  benign strictures. 
Retrievable Metal stents (Song et al) are now in market these also useful for benign strictures. Stent 
with chemotherapy coating is under trial whether it will alter the course of disease is to be tested by 
time. 
CONCOMITANT PALLIATION
This review of lumen restoration procedures for malignant oesophageal obstruction would be 
incomplete without emphasizing concomitant measures so essential to care of the "whole patient." Pain 
relief and nutrition support must be continued throughout the palliative treatment program. 
PAIN THERAPY
Pain due to  the primary carcinoma and/or  regional  metastases  is  a  major  problem in these 
diseases. Pain typically becomes serious enough to require regular drug therapy relatively late in the 
course but may occur in 10% as the first symptom preceding dysphagia (90). It is ordinarily a constant, 
deep,  aching,  or  boring pain  noted  in  the  retrosternal  area  and may be  referred  to  neck,  jaws,  or 
shoulders. This pain responds incompletely to medications like aspirin or acetaminophen plus codeine 
analogues.  In the later  stages, morphine sulfate,  methadone,  or other potent narcotics are required. 
Liquid morphine or other liquid analgesic preparations are most useful in patients with dysphagia. A 
sedative at bedtime may help by enhancing the analgesic effect of a narcotic drug. These debilitated 
patients should be encouraged to use analgesics as needed to be kept comfortable, but they should be 
observed closely for narcotic side effects. The risk of addiction is low and should not influence the 
need for adequate pain relief. The extreme fatigue suffered by these patients due to pain and insomnia 
can be relieved only by an effective pain management regimen. 
NUTRITIONAL SUPPORT
The patient's nutritional status should be assessed periodically. Treatment of the protein and 
calorie malnutrition, so common in these patients should be initiated early. Depending on overall status 
and  prognosis,  it  may  be  appropriate  to  begin  this  restoration  by  a  percutaneous  endoscopic 
gastrostomy/jejunostomy, by a nasoenteric feeding tube (90) or, rarely, by central venous alimentation. 
Oral feeding is encouraged as tolerated at the same time, although the tumor-related anorexia and pain 
often create major obstacles to achieving adequate nutrition. Early deaths may result as much from the 
consequences of malnutrition and infection, especially pneumonia, as from spread of the carcinoma. 
Other important aspects of supportive care include maintenance of good oral hygiene, adequate 
dentition,  and  pulmonary  toilet.  The  care,  compassion,  and  ready availability  of  a  knowledgeable 
physician who can provide psychological support for the patient and concerned family members are 
important to the quality of the patient's remaining life. 
AIM OF THE STUDY
1. To study the role of Self Expandable Metal Stents for Palliation in Cancer Oesophagus patients.
2. To  study  the  effectiveness  of  Self  Expandable  Metal  Stents  in  oesophago-respiratory  fistula 
associated with Cancer Oesophagus.
3. To study the procedural success of placement of Self  Expandable Metal  Stent in  Patients  with 
Carcinoma of the Oesophagus.
4. To study the complications following Self Expandable Metal Stent placement for carcinoma of the 
oesophagus.
5. To study the effect of placing Self Expandable Metal Stent without Antireflux Valve across the 
Oesophagogastric Junction.
6. To study the effect  of placing Self  Expandable Metal  Stent  in the upper Oesophageal  tumours 
within 2 cm of upper Oesophageal Sphincter.
MATERIALS AND METHODS
STUDY PROTOCOL:
This  study  was  conducted  in  Department  of  Digestive  Health  &  Diseases  a  prestigious 
department with rich heritage located in the Government Peripheral Hospital, Anna Nagar, Chennai- 
600 102, attached to Government Kilpauk Medical College, Chennai. The study conducted exclusively 
in Department of Digestive Health & Diseases inpatients and the patients were subsequently followed 
as out patients.
The Study period was May 2003 to August 2005. The patients belonged to two groups. First 
group patients were referred from other hospitals. Department of Digestive Health & Diseases is the 
referral center to Government Kilpauk Medical College Hospital, Chennai; Government Royapettah 
Hospital,  Royapettah,  Chennai; ESI Hospital in Ayanavaram, Chennai; ESI Hospital  in KK Nagar, 
Chennai; Government Peripheral Hospital, Periyar Nagar, Chennai; Government Chest Hospital, Ooteri 
and many Government Institutions all over the State. Second group of patients presented themselves to 
Department of Digestive Health & Diseases due to their GI symptoms. 
INVESTIGATIONS:
As per our hospital protocol any patient with gastrointestinal symptoms with warning signals 
such as anemia, loss of appetite, loss of weight, dysphagia, vomiting, blood vomitus, melenic stool and 
patients more than 40 years even without warning signals are investigated. In any patient with clinical 
suspicion of carcinoma oesophagus investigation starts from Hemogram (Hemoglobin, Total Count, 
Differential Count, ESR, Reticulocyte Count, Peripheral Smear, Platelet Count) then Plain Chest X-
Ray and Barium Swallow (Fig- 1 to 10)  ordered (thick barium, thin barium & mucosal relief films in 
various views like RAO, LAO, PA, Lateral) which may show any suspicious lesions in the form of 
filling defect, ulceration, axis deviation, fistulous communication with respiratory tract, contour defect, 
luminal dilatation above lesion, gastric fundic air shadow contour abnormalities, aspiration changes 
(consolidation, air bronchogram & infiltration) and any signs of metastasis into lung or mediastinal 
nodes. 
VIDEO-ENDSOCOPY:
After  suspicious  Barium swallow study patient  posted for  Upper  GI endoscopy study.  Our 
department is equipped with Videoendoscopy system from Pentax (Model EG-291 P) (Fig- 11, 12) and 
corresponding processor (Pentax EPK-150 C) (Fig- 13, 14). Our videoendoscopy system (Fig- 15) has 
an excellent optics. Reporting of endoscopy is done manually in our department. As per our department 
protocol Videoendoscopy done as inpatient procedure, if the patient was undergoing any therapeutic 
procedure (Dilatation) the patient was kept under observation if not patient is discharged on the same 
day. Videoendoscopy usually is done after overnight fasting. 
SAME SITTING DILATATION:
If the patient was having obstructive symptoms and videoendoscopy showed growth obstructing 
the lumen, then after taking biopsy lumen restoration is carried out with wire guided poly vinyl bougie 
dilation using Savary-Gilliard (SG) dilators (Fig- 16). Dilatation done under two methods one is under 
fluoroscopic guidance (our department is provided with 1000 MMA machine & a C- Arm) (Fig- 17, 
18) in which guide wire in a cannula or 7Fr SG dilator negotiated through the stricture/ narrowing, it is 
best  for initial dilation,  tortuous lesions, complex anatomy (Fig- 19, 20 ,21,22); another method is 
under endoscopic in which Guidewire placed under endoscopic guidance and over that dilatation is 
proceeded, it was adapted only for subsequent dilatations, straight lesions, without fistula. Routinely 
after dilatation check Chest X Ray taken unless dilatation is done under fluoroscopic guidance where 
we can confirm that at the dilatation table itself. If any suspicion of perforation thin contrast study is 
performed.
NASOGASTRIC TUBE PLACEMENT:
If the patient was having a very tight stricture, high chance of early recurrence of stricture, 
dilatation done < 12.8 mm dilators and more importantly in the patient with oesophago-respiratory 
fistula, naso- gastric tube placed in the same session after dilatation and its position was confirmed by 
clinical examination. It is important in order to continue feeding in this group of patients.
HISTOPATHOLOGY:
In  Videoendoscopy,  if  any suspicious  lesions  in  the  form of  large  ulcers,  nodular  growth, 
proliferative growth, ulceroproliferative growth are found (Fig- 23 to 30), biopsy is taken from the 
representative lesions. In our department we are using routine biopsy forceps, upto 6 specimens are 
taken from the growth. The biopsy specimens are mounted in a tissue paper fixed in formalin and sent 
to our pathology department. After histopathologic report, the correlation with endoscopic finding is 
between 80-95% of our cases. Biopsy negative is due to insufficient tissue due to gritty lesion, friable 
tissue or rarely the lesion is due to some benign disease mimicking malignancy. Biopsy is repeated if 
the suspicion is high.
THE STAGING & ASSESSMENT OF OPERABILITY:
Operability is assessed by helical thin multi slice CT scan (54) of the chest and abdomen (Fig- 
31-  34).  Inoperable  lesions  are  those  in  whom  tumour  is  extending  outside  oesophagus  (loss  of 
perioesophageal  fat  plane)  and  into  neighboring  structures  like  trachea  &  respiratory  tract,  aorta, 
pericardium, pleura, lung and spine (T4); Involvement of nodes- Mediastinal nodes (mid Oesophagus 
tumours),  Cervical  Nodes  (Upper  Oesophagus  tumours),  perigastric  nodes,  celiac  nodes  (Lower 
Oesophagus & OG Junction tumours); Metastasis into lung, liver & lymphangitis carcinomatosa are 
picked by CT.   
Other  than  CT even  barium swallow findings  such  as  length  >  5cm,  tortuous  lesion,  axis 
deviation, oesophago-respiratory fistula and metastasis in mediastinal nodes or lung secondaries rule 
out  a  chance  of  curative  resection.  In  an  ideal  setting  staging  should  be  done  with  endoscopic 
ultrasonogram (54) which picks up T1, T3, T4 stage tumours accurately but its sensitivity for T2 lesion 
is  not  accurate.  Other  investigations  used  for  staging  are  MRI  (54)  and  PET (Positron  Emission 
Tomography) (54).
OPERABLE TUMOUR:
After staging the tumour, if it was found to be an operable lesion the patient was referred to 
Surgical oncology department/ Surgical gastroenterology department. 
INOPERABLE TUMOUR:
If  the  lesion  appears  to  be  inoperable  by  CT  scan,  Surgical  Gastroenterologist  /  Surgical 
Oncologist opinion is sought to rule out any possibility for curative resection and if branded inoperable 
patient is taken up for palliative treatment.
WIRE GUIDED DILATATION & FEEDING:
If the patient was having difficulty in swallowing patient was taken for endoscopic luminal 
restoration procedure. In our department Endoscopic Dilatation is done using the Rule of "3" (Fig- 19 - 
22) (three next size dilatation after the dilatation with some resistance). Ideal goal in dilatation is to 
reach 15 mm dilatation but that  could not  be achieved in all  patients  even after  weekly dilatation 
sessions due to the rapid rate of growth of tumour. Complications after dilatation do occur. So it is our 
policy to put naso-gastric feeding tube of 20-22 G size after dilatation since it may prevent complete 
closure of the lumen prevents frequent dilatation sessions and related complications and aids in the 
healing  of  oesophago-respiratory  fistula  associated  with  the  tumour  and  overcomes  the  anorexia 
associated with  cancer.  In  inoperable  patients  after  lumen restoration and NG tube placement  and 
proper advice to the patients regarding the feeding formula (high caloric, balanced, mineral and vitamin 
supplements),  frequency of  feeding  (hrly  feeding,  nocturnal  feeding,  consistency of  formulas)  and 
complications (tube blockage, Reflux, aspiration, ear pain, glue ear, sore throat) are given. 
THE ELIGIBILITY FOR A FREE SEM STENT: 
Self Expandable Metal Stents are sponsored by the Government of Tamil Nadu under "Chief 
Minister's Illness Fund for Cancer Patients". The patients eligible for Self Expandable Metal Stent must 
be a Resident of Tamil Nadu State and his/ her annual income must not exceed 10,000 Rupees. The 
patient should produce his/her original Ration Card and attested Xerox copies (proof of address) and an 
income certificate issued by an Revenue  department officer of the rank not below Thasildhar and if 
necessary  an  Nativity/  Residence  certificate  issued  by  Village  Administrative  Officer/  Municipal 
Commissioner depending on the locality. 
THE STENT:
The stent used in this study is "CHOO ESOPHAGEAL COVERED STENT"- KOREA (Fig- 35 
- 41). 
CHOO STENT DESIGN:
Material  : Nitinol (Nickel 55% & Titanium 45%)
Design  : Tubular Wire Mesh Prosthesis with polyurethane    
   membrane constrained in the sheath over a catheter.
Assembly : 18 Fr (6mm) size & wire guided.
Flexibility  : Highly Flexible Fits to the curvatures
Radial Force  : High Radial Expansile Force   
Covering  : Covered with Polyurethane Membrane in the usable 
   Length, both ends are not covered to prevent migration. 
Retrievable : Yes. Nylon Lasso wires present in both ends.
Delivery : Distal release type.
Stent Length  : 8/ 11 / 14 / 17 cm- Usable length 4 / 7 / 10 / 13
Expanded diameter : 18 mm
Shortening : Minimal
Flaring : 6 mm Proximal and Distal- Anti Migration Property
Delivery System : Inner Shaft- 70 cm, Outer Sheath- 6mm with a safe lock    
  And a Distal Olive Point
THE PROCEDURE:
After overnight fasting or minimum 6-8 hr fasting patient was taken into the endoscopy theatre. 
First the procedure was explained to the patient. The written consent from the patient was obtained. 
Then the patient was put in the left lateral position in the endoscopy table. The naso-gastric tube if 
present was removed after  aspiration.  The Self  Expandable Metal  Stent can be deployed by either 
ENDOSCOPIC OR FLUOROSCOPIC METHOD:
ENDOSCOPIC METHOD (Fig- 41- 48):
 Video endoscope advanced into the oesophagus till the site of narrowing.
 The proximal  margin of  growth from the  incisors  measured  and the  lumen of  the  oesophagus 
assessed.
 Endoscope negotiated through the growth, observing the mucosa in the length of the tumour.
 If any oesophago-respiratory fistula present the site of the fistula from the incisors measured. 
 If not possible to negotiate the growth the guide wire placed and Savary- Gilliard dilatation done 
upto 9 mm at the maximum to 11 mm (32).
 After  dilatation  endoscope  negotiated  through  growth  and  distal  margin  was  measured  from 
incisors.
 Endoscope advanced into the stomach, in the stomach retroflexed view of the fundus and cardia to 
look for any extension of the growth into stomach.
 Stomach further screened to find if there are any synchronous lesions or metastatic lesions or nodal 
impressions in the stomach and their potential to cause gastric outlet obstruction was assessed.
 Then a 0.035 Zebra Guide wire placed into the duodenum through the endoscope.
 Then  the  scope  removed  at  the  same  advancing  the  guide  wire  to  maintain  its  position  in 
duodenum.   
 During withdrawal of endoscope oesophago-gastric Junction measured and the growth assessed 
more easily due to the stiffness given by the guide wire inside the scope the distal & proximal 
margin of the growth measured, if any oesophago-respiratory fistula present again measured to find 
the exact position. 
 After measuring the length of the lesion Self Expandable Metal Stent's length calculated as follows: 
2cm Proximal + Growth Length + 2 cm Distal = Actual length of the stent needed.
 If the length of the tumour is more than available Self Expandable Metal Stent length, Telescoping 
Stent can be deployed- using two Self Expandable Metal Stents overlap on one another to cover the 
whole length of the tumour.
 The selected length of Self Expandable Metal Stent is threaded over the Guide wire.
 Endoscope placed at the proximal end of Self Expandable Metal Stent in the oesophagus.
 Under the endoscopic guidance the distal release stent was deployed after removing the lock in the 
introducer.
 The position of the stent during deployment can be changed easily before full deployment under 
endoscopic guidance by pulling or pushing the stent introducer.
 After  full  deployment  the  stent  expansion  was  assessed  by endoscope superficially  since  only 
50%-70%  of  deployment  occurs  immediate  after  deployment  and  passing  the  endoscope 
immediately after stent deployment may increase the chance of stent migration.      
FLUOROSCOPIC METHOD (Fig- 49-52):
 Initial Procedure is the same like endoscopic method. 
 During withdrawal of endoscope marking the upper end and lower end of the tumour is marked 
externally with a radio-opaque marker like pin, safety pin. 
 The important thing is that the patient's position should not be changed even a bit since it may 
change the final position of the stent. So the patient should be changed to supine position during 
marking of the ends of the growth and Self Expandable Metal Stent should be deployed in the same 
position.
 Instead of external marking, internal marking done by lipiodol injected endoscopically was used for 
fluoroscopic guidance. This method overcomes the problems with the external markers.
 Fluoroscopic guidance is better than endoscopic guidance since we can watch the total length of the 
stent expansion and positioning is relatively easy during deployment.
POST PROCEDURE CARE:
After the procedure patient was instructed to have head end elevation of 45%-60%. Patient may 
have severe retrosternal pain due to the expanding stent. That should be alleviated by good parental 
analgesics that can be needed to continue for few days. Immediately after stenting hiccup, vomiting, 
cough may increase the chance of migration. So, that should be treated with prokinetic agents and 
antitussives. Patient was kept nil orally for 12- 24 hrs, then plain liquids started followed by liquid food 
then semi solid diet over a few days. 
After 1 day Check X Ray taken (Fig- 53- 56) in Lateral & Right Anterior Oblique views to 
visualize  the  stent  position  and expansion  and  complications  if  any  like  stent  migration  or  under 
expansion are noted. Liquid contrast study was done in cases of fistula. After 3 days patient was taken 
up for upper GI endoscopy to assess the stent position. If any changes are to be made can be done by 
pulling/ pushing the Lasso wire by Rat Tooth Forceps. 
INSTRUCTIONS AT DISCHARGE:
At discharge patient was instructed about food habits, to take only semisolid diet, after mashing 
or thorough chewing and assist the swallowing by frequent intake of plain water in between swallows. 
To take small feeds but frequent feeds. To avoid lying posture immediately after food and delay going 
to bed by atleast 2-3 hr after food. 
Since the peristalsis  is  hampered by growth infiltrating into the muscular  wall  and by Self 
Expandable Metal Stent holding the wall tightly. Food may impact particularly if taken as food bolus. 
So the patient should be instructed about the food bolus impaction. Patient should be advised about the 
complications like food impaction, aspiration, reflux and stent obstruction by tumour ingrowth and 
overgrowth and stent migration.
For assessing the patient he/she was advised to review at our department out patient clinic once 
in a fortnight/month. 
FOLLOW-UP:
During  the  follow-up  visits  patients  were  asked  about  their  improvement  in  dysphagia, 
nutritional  improvement  (weight  gain),  quality  of  life,  complications  of  procedure  and  disease. 
Improvement in dysphagia was measured by using dysphagia score. Investigation in the form of Chest 
X ray and Upper GI endoscopy was done. Quality of life depends not only on the improvement of 
dysphagia but also the pain control with analgesics and psychological support was also provided.  
TREATMENT OF COMPLICATIONS:
If  food bolus was found to obstruct the lumen, it  was cleared by water jet  and mechanical 
devices like snare, rat tooth forceps. Stent migration can be corrected. Tumour ingrowth/ overgrowth 
can also be treated at the same sitting.  
POST PROCEDURE CHEMO-RADIATION THERAPY:
After Self Expandable Metal Stenting patients were referred for palliative treatment of carcinoma of the 
oesophagus  to  Medical  Oncology  and  Radiation  oncology  departments.  Some  of  the  patients  are 
underwent full course of radiotherapy  with the Self Expandable Metal Stent in situ.  
STUDY OUTLINE
Total number of patients : 30
Male : 18
Female : 12
Male/female ratio : 1.5 : 1
Age group : 35 - 72 years
Mean Age : 52.5 years
Age range in Males : 38 - 72 years
Mean Age in Males : 52.5 years
Age range in Females : 35 - 63 years
Mean Age in Males : 51.7 years
Squamous cell carcinoma : 28
Adeno carcinoma : 02
Stent within 2 cm of UES : 04
Stent extending into stomach : 07
Tumours with oesophago-respiratory fistula : 12
Method of stent release
Endoscopic method : 21
 Fluoroscopic method : 09
Minor Repositioning : 02
Immediate expansion : 30
Immediate complication : 00
Chest Pain : 09
Minor Bleed : 04
Major Bleed : 00
Choking sensation : 05
Gastro Oesophageal Reflux : 11
New Fistula Development : 00
Late complication : 04
Minor Stent Blocking : 03
Tumour In/Over Growth : 00
Stent Migration : 01
Radiotherapy after SEMS : 16
Follow-up : 15 patients




In my study the patients were selected from general patient pool. Inclusion for palliation with 
Self Expandable Metal Stent was any patient with biopsy proven inoperable oesophageal carcinoma 
and the patient must be from lower socio-economic group to be eligible for Self Expandable Metal 
Stent. 
RISK FACTOR
In  my study I  found that  the risk factor  in  14 of  18 male patients  was  smoking,  Tobacco 
chewing in 8 of 12 female patients. Alcohol consumption was found in 10 of 18 male patients and 1 of 
12 female patients. Both tobacco use (smoking/oral) & alcohol were in 8 Male patients and 1 female 
patient.
AGE INCIDENCE & MALE TO FEMALE RATIO (Fig- 57- 59):
Male to Female ratio in my study was 1.5: 1. Age group of patients range from 35- 72 years. 
Mean age was 52.5 years. Age group of male patients range from 38- 72 years and mean age was 53.5 
years. Age group of Female patients range from 35- 63 years and mean age was 51.7 years.
HISTOLOGY OF CARCINOMA OESOPHAGUS (Fig- 60):
In  my study Squamous cell  carcinoma was the predominant  type  of carcinoma (28 cases),  Adeno 
carcinoma of Lower end of oesophagus in 2 cases. Adeno carcinoma constituted 6.6% of total cases 
and Squamous cell carcinoma constituted 93.4% of total cases.  
CARCINOMA OESOPHAGUS WITH OESOPHAGO-RESPIRATORY FISTULA (Fig- 61): 
 In my study 12 cases of carcinoma oesophagus were with oesophago-respiratory fistula. In two 
patients multiple fistulous openings were made out. The etiology was carcinoma oesophagus in all 
cases.  In  the  12  patients  4  had  severe  lower  respiratory  infection  in  the  form  of  pneumonic 
consolidation  with  septicemia  and  poor  nutrition,  other  patients  with  lesser  degree  of  respiratory 
infection. Incidence of oesophago-respiratory fistula in this group was 40% somewhat higher than other 
cases  may  indicate  the  advanced  disease  and  pre  procedure  dilatations  may  predispose  to  that. 
Oesophago-respiratory fistula associated with poor survival. Associated malnutrition has detrimental 
effect on survival.             
METHOD OF STENT DEPLOYMENT (Fig- 62):
The Self Expandable Metal Stent could be deployed by either Fluoroscopic guidance (09) or 
Endoscopic guidance (21). In our department initially Self Expandable Metal Stent deployed under 
Fluoroscopic  guidance.  Later  we used  the  endoscopic  guidance  and  we found that  it  was  equally 
effective and less time to deploy stents and it avoids radiation exposure to the medical personnel & 
patient.  In  this  study,  2  patients  with  Self  Expandable  Metal  Stent  deployed  under  fluoroscopic 
guidance required minor  repositioning of  Self  Expandable Metal  Stent  but  none of the patients  in 
endoscopic guidance group needed repositioning.     
POST PROCEDURE (Fig- 63):
Immediately after Self Expandable Metal Stent placement the expansion of the stent immediate 
after  procedure was good in all  cases (100%). Stent expansion checked after  3 days showed good 
expansion  in  all  cases.  There  was  no  shortening  of  the  stent  after  deployment.  Immediate  post 
procedure  minor  repositioning  of  stents  was  done  in  2  cases.  No  immediate  post  procedure  stent 
migration noted. 
Minor Chest pain was present in all  cases and severe chest  pain in 9 cases (30%). All  the 
patients improved with analgesics for few days. Only few patients required long term analgesics. 
There were no cases of undue major bleed after stent deployment. Stent related minor post 
procedure bleed in 4 cases, stopped without any intervention.  
5 patients had choking sensation after stenting that got relieved by its own in 4 patients, in 
remaining 1 patient it lasted for few months. 4/5 patients with choking sensation had stent with in 2 cm 
of upper oesophageal sphincter.
Among  the  30  patients,  7  patients  had  stent  positioned  into  the  stomach  (2  cases  growth 
extending into stomach and 5 cases lower oesophageal lesion with flange portion of stent extending 
into stomach). In these 7 patients, 3 had reflux symptoms and in the remaining 23 patients 9 were 
symptomatic  (Fig- 64). Totally 12 patients were symptomatic. Life style modifications (small and 
frequent feeds, avoid oily foods at night, food to bed gap of 2 hrs, lozenges/ salivary secretogogues) 
and drugs as prokinetics and Proton pump inhibitors relieved the symptoms. 
LATE COMPLICATIONS (Fig- 65): 
Late complications occurred in 4 patients. 3 patients had stent blockage and 1 patient had stent 
migration.  In all cases of stent blockage it was because of food material obstructing the lumen. The 
blocking food material could be easily removed with water jet, Rat Tooth Forceps, Snare and Dipod 
(usually after fragmenting the food material with any mechanical instrument water jet was used to clear 
the lumen). After removing the debris oesophagus was screened for any tumour ingrowth/ overgrowth. 
In none of the patients we observed any tumour In/Over growth large enough to block the lumen. 
After 1 month of follow-up, one patient came back with dysphagia because of stent migration. 
Chest X-Ray and upper GI endoscopy showed that the stent migrated downwards. At the same sitting 
of upper GI endoscopy stent retrieved with rat tooth forceps by holding the Lasso wire of the stent and 
pulled back in to the desired portion.
 There was no new development of oesophago-respiratory fistula in any of patients in follow-up 
after Self Expandable Metal Stent placement. 
POST PROCEDURE PALLIATION TREATMENT:
After Self Expandable Metal Stent placement the patients were referred to Medical oncology 
and Radiation Oncology Departments. Obviously the 12 patients with oesophago-respiratory fistula 
were  deferred  for  Radiation  therapy  by  the  Radiation  Oncologist  and  they  were  selected  for 
Chemotherapy.  Among  the  18  patients  referred  to  radiotherapy  only  8  patients  underwent  full 
radiotherapy (20-30 fractions, 100 rad/fraction). Of the 12 patients referred to chemotherapy, only 4 
patents took chemotherapy with 5- fluorouracil as a single agent therapy. 5FU was given as a bolus or 
an infusion form.   
During the course of chemo-radiotherapy we were not able to note any change in the stent 
related complications like, perforation, new fistulas, bleeding and aortic fistula.
FOLLOW-UP:
All the 30 patients were advised to be on follow-up in our department. Except 15 patients others 
were lost follow-up at some part of time. 5 patients with oesophago-respiratory fistula and 10 patients 
without oesophago-respiratory fistula turned up for follow-up. At present 5 patients are in follow-up. 
10 patients were admitted with terminal illness in the form of secondaries in lung, bone, liver and brain, 
severe respiratory infection and septicemia. Maximum follow-up in my study was 1yr and 4 months. 
In the fully followed up patients (procedure- Death) and excluding the recently stented patients 
(15-5=10) average survival after stenting was 6month 29days. When dividing the patients into 2 groups 
(Fig- 66) by the presence of oesophagorespiratory fistula. In the oesophagorespiratory fistula group 
average survival was 5 month 5days, in the other group it was 7 month 21 days.  
Dysphagia improvement was noted (3 to 1) grade according to O'Sullivan's score in all  the 
patients. Beside the stent related complications the disease related complications like pain due to local 
extension,  infiltration  of  nerves,  vertebral  invasion  and  secondary  deposits  were  taken  care  by 
analgesics and pain clinic (run by Anaesthesia department). 3 of our patients received Nerve blocks, 
ganglion  block  including  celiac  ganglion  block  for  pain  control.  Psychological  support  was  also 
provided to our patients. But for the pain, all the patients had improvement in quality of life. After all 




The  geographic  variation  in  oesophageal  squamous  cell  carcinoma  strongly  hints  at  the 
contribution of environmental factors, although the genetic basis for the sporadic form of this cancer 
has stared to be elucidated. In my study I found that the risk factor in 14 of 18 male patients was 
smoking, tobacco chewing in 8 of 12 female patients. Alcohol consumption was found in 10 of 18 male 
patients  and  1 of  12 female patients.  Both  tobacco use  (smoking/oral)  & alcohol  were  in  8  Male 
patients and 1 female patient. 
Studies by Burch et al (2), Wynder EL et al (3), Negri E et al (4) show that the tobacco and 
alcohol act independently as risk factors for Cancer oesophagus. When both alcohol and smoking were 
present the risk increases synergistically.      
SOCIO-ECONOMIC STATUS & SEX INCIDENCE:
 In my study the inclusion criteria for palliation with Self Expandable Metal Stent is that the 
patient must be from lower socio-economic group because the stent was sponsored by the Government 
for the economically under privileged group. So, that the epidemiological aspects of my study reflect a 
group of people from lower socio-economic status. 
Male to Female ratio in my study was 1.5: 1. Age group of patients ranged from 35- 72 years 
and mean age was 52.5 years. Age group of male patients ranged from 38- 72 years and mean age was 
53.5 years. Age group of female patients ranged from 35- 63 years and mean age was 51.7 years.
In reviewing the works by, Warwick et al (5), Silber et al (6), Day et al (7) cancer oesophagus is 
common in 6th - 7th decade of life. Carcinoma oesophagus more common in Males than Females (the 
ratio is 2-3: 1). The incidence starts to increase after 40 years of age. It is common in black men than 
other ethnic group in United States probably the socioeconomic status of the black people may have 
some contribution.
In my study all the patients were from lower socio-economic group. Their mean age at the 
diagnosis of cancer was 52.5 years 2 decades earlier than the western group. It may be due to the fact 
that these people were from lower socio-economic group, lack of refrigeration of foods (nitrosamine 
theory) and increased usage of tobacco and alcohol due to lack of awareness and lack of education.       
HISTOLOGY OF CARCINOMA OESOPHAGUS:
In  my study Squamous cell  carcinoma was the predominant  type  of carcinoma (28 cases),  Adeno 
carcinoma of Lower end of oesophagus in 2 cases and the ratio between Squamous cell carcinoma and 
Adeno carcinoma was 1: 0.07. Adeno carcinoma constituted 6.6% of total cases and Squamous cell 
carcinoma constituted 93.4% of total cases.  
According to Greenlee R et al (8), Pera et al (9) overall incidence of oesophageal carcinoma is 
at  an  average  2.2-  4.5  per  1,00,000  population.  Among  these,  squamous  cell  carcinoma  is  the 
predominant type - ratio varying from 5-7:1. Now the incidence of adeno carcinoma is increasing in the 
Western countries. But in my study the adeno carcinoma was less than the existing proportion seen in 
literature. Adeno carcinoma is related to the acid reflux,  Barrett's  oesophagus and high body mass 
index, but these factors were rare in these low socio-economic patients.
CARCINOMA OESOPHAGUS WITH OESOPHAGO-RESPIRATORY FISTULA: 
 In my study 12 cases of carcinoma oesophagus were with oesophago-respiratory fistula and in 
two patients multiple fistulous openings were made out. It was because of carcinoma oesophagus in all 
cases. In the 12 patients, 4 had severe lower respiratory infection, while other patients lesser degree of 
respiratory infection. 
In reviewing literature Gschossmann JM et al (50), Cilley et al (53), incidence of oesophago-
respiratory  fistula  in  cancer  oesophagus  was  5%-15%.  In  some  case  series  oesophago-respiratory 
fistula was reported in about 30% of cases of cancer oesophagus.  Closure of the fistula with stenting in 
66- 100% of cases according to McGrath et al (87) and  Ell et al, (52).
In my study the incidence of oesophago-respiratory fistula was 40%. It was somewhat higher 
than other case series. It may be due to the advanced nature of disease. In all the patients immediately 
after stenting fistula was well covered (100%) evidenced by contrast studies and clinical improvement. 
METHOD OF STENT DEPLOYMENT:
The  Self  Expandable  Metal  Stent  could  be  deployed  by  either  Fluoroscopic  guidance  or 
Endoscopic guidance. In my study in 9 patients, fluoroscopic method and in 21 patients, endoscopic 
method was used. In 2 patients Self Expandable Metal Stent deployed under fluoroscopic guidance 
required minor repositioning of the stent but it was not required in endoscopic guidance group.     
According to Singvi et al (40) endoscopic method for stent deployment is well tolerated and 
technically successful. In reviewing the literature there was no head to head comparison between the 
techniques  of  endoscopic  and  fluoroscopic  stent  deployment.  The  advantage  of  the  fluoroscopic 
method is especially for the stents with fore shortening property. Since we have used the stent without 
such problem and also endoscopic method was the single sitting procedure after guide wire placement 
and it also reduces the risk of radiation. So it was our choice to use endoscopic method for deployment. 
POST PROCEDURE:
IMMEDIATE EXPANSION:
Immediately  after  Self  Expandable  Metal  Stent  placement  the  expansion  of  the  stent  was 
complete  and it  remained so  at  3  days  later  when we screened prior  to  discharge.  There  was  no 
shortening of the stent after deployment. Immediate post procedure minor repositioning of stent was 
done  in  2  cases  (Fluoroscopic  guided  deployment)  due  to  minor  problems  in  fixing  the  external 
markers before deployment. 
According to Duerig T et al (55), Sandock D et al (56), Ramirez et al (59) Nitinol material is 
kink resistant, enable the stent have memory properties and fatigue resistant property of gives tensile 
strength so it ensures the good expansion after deployment. 
In my study the immediate expansion was 100%. It was mainly due to mechanical property of 
the Nitinol stent.
STENT MIGRATION:
No immediate post procedure stent migration was noted in my study. Only minor repositioning 
of the stent due to improper release of the stent due to patient position change during deployment under 
Fluoro guidance was seen.
According to Duerig T et al (55), Ell at al (46) Nitinol is adverse to dynamic interference and 
once deployed, it gently exerts a level of force that prevents recoiling, and this prevents the stent from 
migrating despite peristaltic activity. Coated stents have more migration than uncoated stents. But the 
uncovered flanges in the newer coated stents prevent migration.
In my study the there was no migration (0%). It was mainly due to proper deployment of the 
stent and due to the mechanical property of the Nitinol stent.
MINOR COMPLICATIONS:
CHEST PAIN:
In my study minor chest pain was present in all cases and severe chest pain in 9 cases (30%). 
The majority of patients improved with analgesics for few days but few patients required long term 
analgesics. According to Kozarek et al (47), dull chest pain present in 85% of his patients and severe 
chest pain in 20 % of his patients. It very well correlates with my case series result.
CHOKING SENSATION:
In my study 4/5 patients with choking sensation had stent with in 2 cm of upper oesophageal 
sphincter. That relieved by its own in 4 patients, in remaining 1 patient it lasted for few months. In 
Macdonald et  al  (64) study of 22 cases of stenting near the upper oesophageal sphincter,  93% had 
technical success, 82% had foreign body like sensation. Study conducted by Profili et al (67) in 9 cases 
technical success in 8 and in 1 case stent migrated. According to Shim et al (69), Inaba et al (66), 
Yamamoto et al (71), Goldscmid et al (68), Loizov et al (69), Spinelli et al (70) and Nomori et al (72), it 
was evident that stenting near the upper oesophageal sphincter is well tolerated particularly after the 
arrival of the newer age stent, only mild chest pain, choking sensation and globus sensation present in 
their series. Respiratory compromise due to air way obstruction was noted in 3%- 10% of cases. In some 
patients  with  air  way  compromise  tracheobronchial  stent  along  with  oesophageal  stent  solves  the 
problem, but it is technically demanding. In my study the stenting in this area was well tolerated in all 
these patients but all had only mild symptoms.
MINOR BLEED:
There were no cases with undue major bleed after  stent deployment.  Only 4 cases of stent 
related minor post procedure bleed that too stopped without intervention. According to Cwiekel W et al 
(78), incidence of minor stent related bleed due to the stent expansion into the necrotic tissue in 8- 40% 
depend on the expansion force of the used stent. In my series 13% of my patients had minor bleed.
REFLUX SYMPTOMS:
Among the 30 stented patients, 7 patients had the stent extended into the stomach. In these 7 
patients, 3 had reflux symptoms (3/7=42.8%), and in the remaining 23 patients 9 (9/23=39.1%) were 
symptomatic.  Totally  12  patients  were  symptomatic.  The  symptoms  got  relieved  by  life  style 
modification, Proton pump inhibitors & prokinetics. There was no significant correlation between the 
stent position and reflux symptoms. 
According to Dua et al (73), Osugi et al (74) and Do et al (75) compared the efficacy of the Self 
Expandable Metal Stent with anti reflux valve with stent without such valve for tumours of oesophago-
gastric junction and they concluded that Stent with anti reflux valve was more efficacious in preventing 
the reflux symptoms. According to Laash et al (76), Sabharwal et al (77), Vakil et al (79), Spinelli et al 
(82) and Siersema et al (80,81,83), the beneficial effect of antireflux valve is doubtful in preventing the 
reflux symptoms. But these studies were used small number of cases. Latest study conducted by Homs 
et  al  (84)  (Gastrointestinal  Endosc-  2004)  done  a  randomized  control  trial  comparing  the  Self 
Expandable Metal Stent with anti reflux valve with stent without such valve for tumours of oesophago-
gastric junction and concluded that reflux symptoms equal or more in Stent with anti reflux valve and 
there is more chance for migration.
In my study the reflux symptoms even though high in both the groups it does not statistically 
support the concept of more reflux symptoms in stent traversing the OG junction. When comparing the 
both groups the reflux symptoms the reflux symptoms were higher in the stents placed across the OG 
junction group ( 42.8% Versus39.1%) but it was not statistically significant (p= 0.34)
LATE COMPLICATIONS: 
In my study late complications occurred in 4 patients stent blockage in 3 patients and stent 
migration in 1 patient. 
STENT BLOCK:
Stent blockage was due to food impaction. The blocking food material can be easily removed 
with mechanical devices and water jet. After removing the debris oesophagus was screened. None of 
the patients we observed had any tumour In/Over growth large enough to block the lumen. 
Pellicer F et al (57) and Pocek M et al (58) reviewing these author's report I found that stent 
blocking rate depends on the type of stent (covered or uncovered) and brand of stent (Ultraflex needed 
more  reinterventions  for  stent  blockage).  In  uncovered  stents  the  tumour  ingrowth/  overgrowth 
(10%-40%) were the most common cause of the stent blockage whereas in covered stents the food 
impaction (5-30%) and hyperplastic tissue response (0%-5%) were the common cause. 
My study used the covered stent with very good radial expansive force. So naturally the stent 
block was 10% and it was due to food impaction.   
STENT MIGRATION:
Stent  migration  was  noted  in  1  case.  After  1  month  of  follow-up  that  patient  came  with 
dysphagia, the stent had migrated downwards. Upper GI endoscopy was done and at the same sitting 
stent was retrieved by holding the Lasso wire and repositioned.
According to Ramirez FC et al (59), Winkelbauer FW et al (60), stent migration depend on the 
type of stent (covered or uncovered). In uncovered stents, the stent extend into the submucosa and the 
tumour ingrowth prevents the stent migration, so it was low in incidence (3%-8%). Whereas in covered 
stent the stent migration occurred more commonly, particularly with fully covered type (5-30%). 
In my study the stent migration rate was 3.3%, lower than the published results. It was due to 
the stent design, large uncovered flanges prevent stent migration and it may be due to the insufficient 
follow-up that may under estimate the stent migration rate.
POST PROCEDURE PALLIATION TREATMENT:
After Self Expandable Metal Stent placement the patients were referred to Medical oncology 
and Radiation Oncology Departments. Among the 18 patients referred to radiotherapy only 8 patients 
underwent  radiotherapy.  In  the  patients  who  had  undergone  radiotherapy,  it  was  given  as  20-30 
fractions (100 rads/ fraction). 12 patients were referred to chemotherapy, but only 4 patents underwent 
chemotherapy with 5- fluorouracil as a single agent therapy. 
Among these  patients  5  patients  with oesophago-respiratory fistula  and 10 patients  without 
oesophago-respiratory fistula were under follow-up. At present 5 patients in follow-up. The remaining 
10 patients were lost due to terminal illness. In the remaining 15 patients we lost follow-up at some part 
of time.
During the course of chemo-radiotherapy we were not able to observe any new complications 
like, perforation, new fistulas, bleeding and aortic fistula.
According to Nguyen et al (61), Maier et al (88), Raijman et al (89)  the use of expandable 
metal stents during the chemoradiation therapy, complications like perforation or new fistula or bleed 
are no more common than in any patient without chemo-radiation therapy. But Nishikawa, Tajiri et al 
(63) says that after chemoradiation therapy perforation was 31%, air way compromise in 23% and 
bleeding in 15%.  
In my study there were no complications following chemoradiation therapy. Because in the 
followed  patients  only  12  patients  had  underwent  post  stent  treatment  either  Chemotherapy  or 
radiotherapy but not the both.  The amount of radiotherapy given at our place was also lesser than the 
amount of radiotherapy given in sited reference. Our patients were also poorly compliant after stenting 
since they were able to eat through the mouth and did not bother about the chemoradiotherapy. These 
were the explanations for the lower incidence of complications in my study. 
FOLLOW-UP:
IMPROVEMENT IN DYSPHAGIA:
All  the  30  patients  immediately  after  stenting  dysphagia  improvement  was  (3  to  1)  grade 
according to O'Sullivan's score. Even after few months of follow-up excluding the patients lost follow-
up in the remaining patients dysphagia improvement persisted.
According to Frimberger et al (85), Domschke et al (86), dysphagia score were improved from 
3.3 to 1.2 in their series with various Self Expandable Metal Stents. In my study also I have observed 
that there was a good response in the dysphagia score.
POST PROCEDURE SURVIVAL:
In my study average survival after stenting (in the fully followed up patients from procedure- 
death and excluding the recently stented patients) was 6 month 29 days. When dividing the patients 
into 2 groups by the presence of oesophagorespiratory fistula. In the oesophagorespiratory fistula group 
average survival was 5 month 5days, in the other group it was 7 month 21 days. The survival in the 
oesophagorespiratory  fistula  negative  group was  relatively  better  than  oesophagorespiratory  fistula 
positive group.
According to Warwick et al (5), Shields SJ et al (36) survival in the cancer oesophagus after 
palliation with endoprosthesis vary from 4 months- 11 months. In my study the survival is comparable 
when excluding the patients lost their follow up. The poor survival rate in oesophagorespiratory fistula 
group may be due to the advanced nature of the disease even before stenting. Because of small number 
of patients the study can not effectively address this issue.
PAIN CONTROL & QUALITY OF LIFE:
Pain due to local extension, infiltration of nerves, vertebral invasion and secondary deposits was 
the major problem taken care by analgesics and pain clinic. Psychological support was also provided to 
our patients. Quality of life in all these patients improved.
According to Bethge N et al (62), Knyrim K et al (44), a significant improvement in Karnofsky 
performance score and HRQOL (Health Related Quality Of Life) after Self Expandable Metal Stenting 
in cancer oesophagus. Even though I have not used any performance score in my study, in general the 
patient’s quality of life improved due to relief of dysphagia and other supportive measures like pain 
relief and psychological support. 
CONCLUSION
1. Self Expandable Metal Stents for Palliation in Carcinoma Oesophagus gives excellent relief of 
dysphagia and provides good quality of life to these patients. There is improvement in general 
well being by allowing the patient to eat and offers better aesthetic appeal.
2. Self  Expandable Metal  Stents  in  oesophago-respiratory fistula  completely covers the fistula 
immediately  after  the  procedure.  It  improves  the  general  condition,  controls  respiratory 
infection, improves the nutritional state and offers good quality of life in these patients with 
Carcinoma Oesophagus.
3. Procedural success of deploying Self Expandable Metal Stent in patients with Carcinoma of 
Oesophagus is good. It is very convenient and easy to deploy the stent and is less cumbersome 
too.  Excellent  expansion  of  the  stent  occurs  immediately  after  deploying  and  relieves  the 
dysphagia in the immediate post procedure period. 
4. Complications  following  proper  placement  of  Self  Expandable  Metal  Stents  for  carcinoma 
oesophagus  are  minimal  but  they  are  well  managed.  No  major  immediate  post  stenting 
complications occurred in my study. Expected number of late complications in the form of stent 
blockage and stent migration occurred but they were managed well.
5. There is no increase in the incidence of reflux symptoms in the group where stents without any 
anti reflux mechanism are placed across the Oesophagogastric Junction.
6. There are only minor complications in the form of choking sensation when the Self Expandable 
Metal  Stent  properly  placed  in  the  upper  Oesophageal  Lesion  within  2  cm  of  upper 
Oesophageal Sphincter.
BIBILIOGRAPHY
1. Malkan G, Mohandas KM, Epidemiology of digestive cancers in India. 1. General principles and 
esophageal cancer. Indian J Gastroenterology. 1997;16:98-102.
2. Burch PRJ et al- oesophageal cancer in relation to cigarette and alcohol consumption, J Churon Inst 
1984;37:793.
3. Wynder EL, Mabuchi K et al. Etiological and environmental factors in cancer oesophagus- JAMA, 
1973;266:1546.
4. Negri E, La Veechia C, Franceschi S et al - Attributable risks for oesophageal cancer in northern 
Italy- Eur J cancer, 1992;28A:1167.  
5. Warwick GP et al. Some aspects of epidemiology and aetiology of the oesophageal cancer, Adv 
Cancer Res, 1973;17:81.
6. Silber W et al - Carcinoma of oesophagus: Aspects of epidemiology and aetiology, Proc Nutr Soc 
1985;44:101.
7. Day  NE,  Munoz  N  et  al.  Cancer  epidemiology  and  prevention,  Philadelphia,  WB  Saunders, 
1982:596.
8. Greenlee  R,  Murray  T,  Bolden  S  et  al-  Cancer  statistics,  2000,  carcinoma  cancer  J  clin 
50(1):7-33-2000.
9. Pera M, Cameron AJ, Trastek VF et al. Increasing incidence of adeno carcinoma of the oesophagus 
and oesophago-gastric junction. Gastroenterology 1993;104:510-513.
10. Swaroop  VS,  Deasi  DC,  Mohandas  KM,  Dhir  V,  Deshpande  RK,  Desai  PB.  Dilatation  of 
esophageal strictures induced by radiation injury for cancer of the esophagus. Gastrointest Endosc. 
1994;40:311-315.
11. Moses FM, Peura DA, Wong RKH et al. Palliative dilation of esophageal carcinoma. Gastrointest. 
Endosc. 1985; 31: 613. 
12. Mohandas KM, Shanthi Swaroop V, Desai DC. Marked wire guided esophageal dilatation and the 
need for fluoroscopy. Gastrointest Endosc. 1992;38:634-635.
13. Heit HA, Johnson LF, Siegel SR, et al. Palliative dilation for dysphagia in esophageal carcinoma. 
Ann Intern Med. 1978;89:629-631. 
14. Cassidy  DE,  Nord  HJ,  Boyce  HW.  Management  of  malignant  esophageal  strictures:  role  of 
esophageal dilation and peroral prosthesis. Gastroenterology 75:173. 
15. Ahmed  ME,  Gustavsson  S.  Current  palliative  modalities  for  esophagal  carcinoma.  Acta  Chir. 
Scand. 1990; 156: 958. 
16. Kubba AK, Krasmer N. An update in the palliative management of malignant dysphagia. Eur. J. 
Surg. Oncol. 2001; 26: 11629. 
17. Boyce HW Jr. Palliation of advanced esophageal cancer. Semin Oncol.;11:186-195. 
18. Dallal  HJ,  Smith GD, Grieve DC et  al.  A randomized trial  of  thermal  ablative therapy versus 
expandable  metal  stents  in  the  palliative  treatment  of  patients  with  esophageal  carcinoma. 
Gastrointest. Endosc. 2001; 54: 549-57. 
19. Fleischer  D,  Kessler  F,  Haye  O.  Endoscopic  Nd:YAG  laser  therapy  for  carcinoma  of  the 
esophagus: a new palliative approach. Am J Surg. ;143:280-283. 
20. Ell  C, Riemann JF,  Lux G, et  al.  Palliative laser treatment  of malignant  stenoses in  the upper 
gastrointestinal tract. Endoscopy. 1986(suppl):21-26. 
21. Loizou LA, Grigg D, Atkinson M, et al. A prospective comparison of laser therapy and intubation 
in endoscopic palliation for malignant dysphagia. Gastroenterology. 1991;100:1303-1310. 
22. Cottier DJ, Carter CR, Smith JS, et al. The combination of laser recanalization and endoluminal 
intubation in the palliation of malignant dysphagia. J R Coll Surg Edinb. 1997;2:19-20. 
23. Adam A, Ellul J, Watkinson AF, et al. Palliation of inoperable esophageal carcinoma: a prospective 
randomized trial of laser therapy and stent placement. Radiology. 1997;202:344-348. 
24. Savage AP, Baigrie RJ, Cobb RA, et al. Palliation of malignant dysphagia by laser therapy.  Dis 
Esophagus. 1997;10:243-246. 
25. Harbord  M,  Dawes  RF,  Barr  H  et  al.  Palliation  of  patients  with  dysphagia  due  to  advanced 
esophageal  cancer  by endoscopic  injection  of  cisplatin/epinephrine  injectable  gel.  Gastrointest. 
Endosc. 2002; 56: 644-51. 
26. Lightdale CJ, Heier SK, Marcon NE, et al. Photodynamic therapy with porfimer sodium versus 
thermal  ablation therapy with Nd:YAG laser for palliation of  esophageal  cancer:  a  multicenter 
randomized trial. Gastrointest Endosc. ;42:507-512. 
27. Payne-James JJ, Spiller RC, Misiewicz JJ, et al. Use of ethanol-induced tumor necrosis to palliate 
dysphagia in patients with esophagogastric cancer. Gastrointest Endosc. 1990;36:43-46. 
28. Overholt  BF.  Photodynamic  therapy  and  thermal  treatment  of  esophageal  cancer.  Gastrointest 
Endosc Clin North Am. 1992;2:433-455. 
29. Scheider DM, Siemens M, Cirocco M, et  al.  Photodynamic therapy for the treatment of tumor 
ingrowth in expandable esophageal stents. Endoscopy. ;29:271-274. 
30. Marcon NE. Photodynamic therapy and cancer of the esophagus.  Semin Oncol. 1994;21(6 suppl 
15):20-23. 
31. Conio M, Gostout CJ. Photodynamic therapy for the treatment of tumor ingrowth in expandable 
esophageal stents. Gastrointest Endosc. 1998;48:225. 
32. Raijman I, Siddique I, Ajani J et al. How much dilatation is necessary prior to placement of an 
esophageal stent? Gastrointest Endosc. 1997;45:213.
33. O'Connor T, Watson R, Lepley D, et al. Esophageal prosthesis for palliative intubation. Arch Surg. 
1963;87:275-279. 
34. Earlam R, Cunha-Melo JR. Malignant oesophageal strictures: a review of techniques for palliative 
intubation. Br J Surg. 1982;69:61-68. 
35. O'Connor T, Watson R, Lepley D, et al. Esophageal prosthesis for palliative intubation. Arch Surg. 
1963;87:275-279. 
36. Shields SJ. Esophageal self-expandable metallic stents. Gastrointest Endosc. 1997;45:439-442. 
37. Cotton PB. Metallic mesh stents: is the expanse worth the expense? Endoscopy. 1992;24:421-423. 
38. Fleischer DE. Stents, cloggology, and esophageal cancer. Gastrointest Endosc. 1996;43:258-260. 
39. Atkinson  M,  Ferguson  R.  Fiberoptic  endoscopic  palliative  intubation  of  inoperable 
oesophagogastric neoplasms. Br Med J. 1977;1:266-267. 
40. Singhvi  R,  Abbasakoor  F,  Manson JM.  Insertion  of  self-expanding  metal  stents  for  malignant 
dysphagia: assessment of a simple endoscopic method. Ann. R. Coll. Surg. Engl. 2000; 82: 2438. 
41. Mosca F, Consoli A, Persi A, portale TR. Comparative retrospective study on the use of plastic and 
Self Expandable Metal Stents in the palliative treatment of malignant strictures of the esophagus 
and cardia. Dis Esophagus. 2003;16:119-125.      
42. Angueria CE, Kadakia SC. Esophageal stents for inoperable esophageal cancer- which to use? Am 
J Gastroenterol 1997;92:373-760
43. DePalma GD, DiMatteo, Romano G et al. Plastic prosthesis versus expandable stents for palliation 
of inoperable esophageal thoracic carcinoma- a controlled prospective study. Gastrointest Endosc 
1996;43:478-82.
44. Knyrim K, Hans-Joachim W, Bethge N et al. A controlled trial of an expandable metal stent for 
palliation of esophageal obstruction due to inoperable cancer. N Engl J Med 1993;339:1302-07.
45. Vermeijden  J,  Bartelsman  J,  Fockens  P  et  al.  Self  expanding  metal  stents  for  palliation  of 
esophagocardial malignancies. Gastrointest Endosc 1995;41:58-63.
46. Ell C, Hochberger J, May A et al. Coated and uncoated Self Expandable Metal Stents for malignant 
stenosis in the upper GI tract preliminary clinical experience with Wallstents. Am J Gastroenterol 
1994;89:1496-1500.  
47. Kozarek R, Ball T, Patterson D. Metallic Self expanding stent application in the upper GI tract- 
Caveats and concerns. Gastrointest Endosc 1994;38:1-6.
48. Raijman  I,  Siddique  I,  Ajani  J  et  al.  Palliation  of  malignant  dysphagia  and  fistula   with  the 
Wallstent- experience with 101 patients. Gastrointest Endosc 1997;45:215A.
49. Little  AG,  Ferguson MK,  DeMeester  TR et  al.  Esophageal  carcinoma with  respiratory fistula. 
Cancer 1984;53:1322-28
50. Gschossmann  JM  et  al-  Malignant  oesophago-respiratory  fistula  in  patients  with  oesophageal 
cancer: Cancer 1993; 24: 127-32.
51. Macken  E,  Gevers  A,  Hiele  M,  et  al.  Treatment  of  esophagorespiratory  fistulas  with  a 
polyurethane-covered self-expanding metallic mesh stent. Gastrointest Endosc. 1996;4:324-326. 
52. May A,  Ell  C.  Palliative  treatment  of  malignant  esophagorespiratory fistulas  with Gianturco-Z 
stents:  a  prospective  clinical  trial  and  review of  the  literature  on  covered  metal  stents.  Am J 
Gastroenterol. 1998;93:532-535. 
53. Cilley et al- Cause of death  in carcinoma oesophagus- Am J Gastroenterol- 1989; 25:527-37.
54. Rankin S, Mason R. Staging of esophageal carcinoma. Clin. Radiol. 1992; 46: 3737. 
55. Duerig T et al- Super elastic Nitinol for medical devices- medical plastics and biomaterials, 1997
56. Sandock D et al- Tubular medical prosthesis for use in a body lumen- United States Patent 5,800, 
519
57. Pellicer  F  et  al-  Self  Expandable  Oesophageal  Metal  Stents  in  the  palliative  treatment  of 
oesophageal cancer. Rev. Esp. Enferm Dig, 1996: 34-57
58. Pocek M et al- Palliative treatment of neoplastic strictures by Self Expandable Nitinol Stent, Eur 
Radiol 1996; 34: 453-462.
59. Ramirez FC et al- Esophageal Self Expandable Metal Stents - indications, practice, techniques and 
complications; Results of a national survey- Gastrointest endosc- 1997; 39: 243-53.
60. Winkelbauer FW et al- Palliative treatment of obstructing esophageal cancer with nitinol stents: 
value, safety, and long term results. AJR Am J Roentgenol- 1996; 23: 234-41.
61. Nguyen et al- The use of expandable metal stents during the chemoradiation therapy- Gastroenterol. 
1998; 114.
62. Bethge N et al- A prospective trial of Self Expandable Metal Stents in the palliation of malignant 
esophageal obstruction after failure of primary curative therapy. Gastrointest Endosc- 1994.
63. Nishikawa Y, Tajiri IH, Endo H et al. Significance and problems of Self Expandable Metal Stents 
for esophageal cancer after chemoradiotherapy. Gastrointest Endosc. 2001; 53: AB156. 
64. Macdonald et al, Edwards RD, Moss JG. Patient tolerance of cervical esophageal metallic stents. J 
Vasc Interv Radiol. 2000;11:891-898.
65. Shim CS, Jung IS, Bhandari S, Ryu CB, Hong SJ, KIM JO, Cho JY, Lee JS, Kim Boston Scientific. 
Management of malignant strictures of cervical esophagus with a newly designed self expanding 
metal stent. Endoscopy;2004;36:554-557.
66. Inaba Y, Kamata M, Aramaki T, Takaki H. Cervical  esophagus stent placement via a retrograde 
Transgastric route. Br J Radiol. 2004;77:787-789.
67. Profili S, Meloni GB, Feo CF, Ginesu GC. Self Expandable Metal Stent in the management of 
cervical esophagus and hypopharyngeal strictures. Clin Radiol.2002;57:1028-1033.
68. Goldschmid  S,  Boyce  HW  Jr,  Nord  HJ,  et  al.  Treatment  of  pharyngoesophageal  stenosis  by 
polyvinyl prosthesis in. Am J Gastroenterol. 1988;83:513-518. 
69. Loizou LA, Rampton D, Bown SG. Treatment of malignant strictures of the cervical esophagus by 
endoscopic intubation using modified endoprostheses. Gastrointest Endosc. 1992;38:158-164. 
70. Spinelli P, Cerrai FG, Meroni E. Pharyngo-esophageal prostheses in malignancies of the cervical 
esophagus. Endoscopy. 1991;23:213-214. 
71. Yamamoto R, Tada H, Kishi A, Tojo T. Double stent for combined esophago-airway lesion. Jpn J 
Thorac Cardiovasc Surg. 2002;50:1-5.
72. Nomori H, Horio H, Imazu Y, Sumasu K. Double stenting for esophageal and tracheobronchial 
stenoses. Ann Thorac Surg. 2000;70:1803-1807. 
73. Dua KS, Kozarek R, Kim J, Evans J, lang I, Hogan WJ. MCW Self Expandable Metal esophageal 
Stent with anti-reflux mechanism. Gastrointest Endosc. 2001;53:603-613.
74. Do  YS,  Choo  SW,  Suh  SW,  Kang  WK,  Rhee  PL  et  al.  Malignant  esophagogastric  junction 
obstruction:  Palliative  treatment  with  an  anti  reflux  valve  stent.  J  Vasc  Interv  Radiol. 
2001;12:647-651.
75. Osugi  H,  Lee  S,  Tokuhara  T,  Kaseno S,  Takada  N et  al.  Usefulness  of  SEM with  antireflux 
mechanism as a palliation for malignant strictures at the gastroesophageal junction. Surg Endsosc. 
2002t;16:1478-1479.
76. Laasch HU, Marriott  A,  Wilbraham L et  al.  Effectiveness  of  open versus  antireflux  stents  for 
palliation of distal esophageal carcinoma and prevention of symptomatic gastroesophageal reflux. 
Radiology 2002; 225: 35965. 
77. Sabharwal T, Hamady MS, Chui S et al. A randomised prospective comparison of the flamingo 
Wallstent and Ultraflex stent for palliation of dysphagia associated with lower third esophageal 
carcinoma. Gut 2003; 52: 9226. 
78. Rozanes I, Poyanli A, Acunas B. Palliative treatment of inoperable malignant esophageal strictures 
with  metal  stents:  one  center's  experience  with  four  different  stents.  Eur.  J.  Radiol.  2002;  43: 
196203. 
79. Vakil  N,  Morris  AI,  Marcon  N  et  al.  A  prospective,  randomized,  controlled  trial  of  covered 
expandable  metal  stents  in  the  palliation  of  malignant  esophageal  obstruction  at  the 
gastroesophageal junction. Am. J. Gastroenterol. 2001; 96: 17916. 
80. Siersema PD, Hop WCJ, van Blankstein M et al. A comparison of three types of covered metal 
stents  for  the  palliation  of  patients  with  dysphagia  caused  by  esophagogastric  carcinoma:  a 
prospective, randomized study. Gastrointest. Endosc. 2001; 54: 14553. 
81. Siersema PD, Marcon N, Vakil N. Metal stents for tumors of the distal esophagus and the gastric 
cardia. Endoscopy 2003; 35: 7985.
82. Spinelli  P,  Cerrai  FG,  Ciuffi  M,  et  al.  Endoscopic  stent  placement  for  cancer  of  the  lower 
esophagus and gastric cardia. Gastrointest Endosc. ;40:455-457. 
83. Siersema PD, Hop WC, Dees J, et al. Coated self-expanding metal stents versus latex prostheses for 
esophagogastric cancer with special reference to prior radiation and chemotherapy: a controlled, 
prospective study. Gastrointest Endosc. 1998;47:113-120. 
84. Homs MY, Wahab PJ, Kuipers EJ, Grool TA, Siersema PD et al. Esophageal stents with antireflux 
valve for tumours of distal esophagus and gastric cardia/; a randomized trial. Gastrointest Endosc. 
2004;60:695-702. 
85. Frimberger E, Expanding spiral: a new type of prosthesis for the palliative treatment of malignant 
esophageal stenosis. Endoscopy. 1983; 15: 213-214.
86. Domschke W, Forster EC, Matek W et al. Self Expandable Mesh Stent for the esophageal cancer 
stenosis. Endoscopy. 1990; 22: 134-136.
87. Mc Grath JP, Browne M, Riordan C et al. Expandable metal stents in the palliation of malignant 
dysphagia and esophageal-respiratory fistulae. Ir. Med. J. 2001; 94: 2702.
88. Maier  A,  Anegg  U,  Lunzer  R  et  al.  The  effect  of  external  beam irradiation  after  endoscopic 
palliation of esophageal carcinoma. Oncol. Rep. 2000; 7: 3759. 
89. Raijman  I,  Siddique  I,  Lynch  P.  Does  chemoradiation  therapy  increase  the  incidence  of 
complications  with  self-expanding  coated  stents  in  the  management  of  malignant  esophageal 
strictures? Am J Gastroenterol. ;92:2192-2196. 
90. Loizou LA,  Rampton D,  Atkinson M,  et  al.  A prospective  assessment  of  quality  of  life  after 
endoscopic intubation and laser therapy for malignant dysphagia. Cancer. 1992;70:386-391. 
                                    PROFORMA
PALLIATION OF CARCINOMA OESOPHAGUS WITH SELF 




























BRAND OF THE STENT:
LENGTH OF THE STENT:
BATCH OF THE STENT:
DATE OF STENT DEPLOYMENT:
























NUMBER OF HOSPITAL ADMISSION:
